title: Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients.
abstract: Thiazolidinediones (TZDs) are a new class of insulin-sensitizing drugs. To explore how and in which tissues they improve insulin action, we obtained fat and muscle biopsies from eight patients with type 2 diabetes before and 2 months after treatment with rosiglitazone (n = 5) or troglitazone (n = 3). TZD treatment was associated with a coordinated upregulation in the expression of genes and synthesis of proteins involved in fatty acid uptake, binding, beta-oxidation and electron transport, and oxidative phosphorylation in subcutaneous fat but not in skeletal muscle. These changes were accompanied by a 13% increase in total body fat oxidation, a 20% decrease in plasma free fatty acid levels, and a 46% increase in insulin-stimulated glucose uptake. We conclude that TZDs induced a coordinated stimulation of fatty acid uptake, oxidation, and oxidative phosphorylation in fat of diabetic patients and thus may have corrected, at least partially, a recently recognized defect in patients with type 2 diabetes consisting of reduced expression of genes related to oxidative metabolism and mitochondrial function.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, Temple University School of Medicine, Philadelphia, PA, USA. bodengh@tuhs.temple.edu
authors.forename: Guenther
authors.initials: G
authors.lastname: Boden
authors.forename: Carol
authors.initials: C
authors.lastname: Homko
authors.forename: Maria
authors.initials: M
authors.lastname: Mozzoli
authors.forename: Louise C
authors.initials: LC
authors.lastname: Showe
authors.forename: Calen
authors.initials: C
authors.lastname: Nichols
authors.forename: Peter
authors.initials: P
authors.lastname: Cheung
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D001692:Biological Transport / Q000187:drug effects; D002839:Chromans / Q000494:pharmacology* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction / Q000187:drug effects; D010085:Oxidative Phosphorylation / Q000187:drug effects; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D000077288:Troglitazone; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D002839:Chromans; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077288:Troglitazone